Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
ReumatologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Rheumatology
- Publicado em
- 26 ago 2024
- Citações
- 37
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Ioannis Parodis, Julius Lindblom, Roger A Levy, Margherita Zen, Nursen Cetrez, Alvaro Gomez, Shereen Oon, Christine Henning, Munther Khamashta, Holly A Quasny et al.
Descritores MeSH
- Remission Induction
- Immunosuppressive Agents
- Lupus Erythematosus, Systemic
- Antibodies, Monoclonal, Humanized
- Middle Aged
- Severity of Illness Index
- Treatment Outcome
- Male
- Female
- Humans
Veja também
Estudos relacionados
- Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data
- Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
- Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life